TCI Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

TCI Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$276	–	1975
2023 Q1	$276	Sell	2 -151	-99%	-$19.6K	﹤0.01%	2299
2022 Q4	$19.8K	Buy	+153	New	+$17.7K	﹤0.01%	712
2022 Q2	–	Sell	-97	Closed	-$8K	–	2502
2022 Q1	$8K	Hold	97	–	–	﹤0.01%	1272
2021 Q4	$9K	Hold	97	–	–	﹤0.01%	1281
2021 Q3	$9K	Buy	97 +2	+2%	+$154	﹤0.01%	1198
2021 Q2	$7K	Buy	95 +91	+2,275%	+$6.9K	﹤0.01%	1243
2021 Q1	$0	Sell	4 -100	-96%	-$9.23K	﹤0.01%	2230
2020 Q4	$18K	Hold	104	–	–	0.01%	521
2020 Q3	$15K	Hold	104	–	–	0.01%	503
2020 Q2	$17K	Hold	104	–	–	0.01%	482
2020 Q1	$10K	Buy	104 +4	+4%	+$457	﹤0.01%	574
2019 Q4	$13K	Buy	+100	New	+$10.1K	0.01%	659
2019 Q2	–	Sell	-3	Closed	–	–	1542
2019 Q1	$0	Buy	+3	New	+$386	﹤0.01%	1544
2018 Q4	–	Sell	-11	Closed	-$2K	–	1640
2018 Q3	$2K	Buy	+11	New	+$1.5K	﹤0.01%	1086

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCI Wealth Advisors's SRPT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 2 shares — an estimated $276 sold.

TCI Wealth Advisors first reported a position in SRPT in Q3 2018 and held it in 14 quarters. The position peaked at $19.8K in Q4 2022. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

TCI Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 2 Sarepta Therapeutics shares in Q2 2023, an estimated $276.
TCI Wealth Advisors first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 14 quarters.
TCI Wealth Advisors's Sarepta Therapeutics position peaked at $19.8K in Q4 2022.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.